This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dynamic Technological Change Is Transforming European Computed Tomography Markets, Finds Frost & Sullivan

LONDON, Oct. 31, 2012 /PRNewswire/ -- The demand for multi-slice computed tomography (CT) systems will drive growth in the European CT market.  Single and dual slice CT scanners are projected to become obsolete in the next two years, while 16 slice and 64 slice scanners will continue to account for a major share of the market over the next 5-6 years.

New analysis from Frost & Sullivan ( http://www.healthcare.frost.com), European Market for Computed Tomography, finds that the market yielded $523.6 million in 2011 and estimates this to reach $691.6 million in 2018. The research covers less than 64 slice scanners (comprising single, dual, 4, 16, 20, 32 and 40 slice CT scanners), 64 slice scanners, 128 and 256 slice scanners and greater than 256 slice scanners.

Continuous technical change has made the market extremely volatile, with several new products being regularly introduced. These new products will increasingly replace single and dual slice CT systems, driving them into obsolescence.

"In the forthcoming years, numerous premium and super premium CT systems will flood the market, sparking demand for high slice CT systems such as 128 and 256 slice scanners," noted Frost & Sullivan Programme Manager Sujith Eramangalath. "These high slice CT systems have superior features in terms of reduced scanning times, lower dosage levels and enhanced image quality."

Different stages of the replacement cycle will aid in the consistent growth of the high slice CT market. Overall, the market will benefit as the range of clinical applications covered by CT will expand. Technological developments supporting superior image quality, coupled with competitive pricing and positive reimbursement policies, will also sustain growth in the CT market over the long-term.

Market growth will, however, be affected by the need for proven clinical results that validate the efficacy of CT. The lack of optimal CT protocols and dearth of skilled personnel will also pose important challenges to market prospects.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,348.94 -2.44 -0.01%
S&P 500 1,953.85 +4.99 0.26%
NASDAQ 4,743.7570 -6.2220 -0.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs